# 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

> **NCT01844700** · PHASE4 · TERMINATED · sponsor: **Northwell Health** · enrollment: 14 (actual)

## Conditions studied

- High Risk MC4R Genotype
- Low Risk MC4R Genotype
- One Week or Less Antipsychotic Lifetime Exposure

## Interventions

- **DRUG:** Ziprasidone
- **DRUG:** aripiprazole, quetiapine, or risperidone

## Key facts

- **NCT ID:** NCT01844700
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** very slow recruitment, no sufficient results
- **Last updated:** 2016-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01844700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01844700, "1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01844700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*